Beta-2 Glycoprotein 1 Antibodies, IgA, Serum
Use
This test is useful for evaluating patients with suspected antiphospholipid syndrome by identifying beta-2 glycoprotein 1 IgA antibodies. It is especially relevant for patients at risk for antiphospholipid syndrome (APS) who are negative for criteria APS tests. Additionally, it helps estimate the risk of thrombosis and/or pregnancy-related morbidity in patients with systemic lupus erythematosus. The presence of these antibodies may be associated with a diagnosis of APS or systemic lupus erythematosus (SLE).
Special Instructions
Not provided.
Limitations
The immunoassays used for the detection of antiphospholipid antibodies, including beta-2 glycoprotein 1 (B2GPI), may not completely distinguish autoantibodies specific for antiphospholipid syndrome from those produced in response to infectious agents, with or without thrombosis. Documentation of persistence as outlined in APS criteria is crucial for clinical evaluation. The use of different commercial immunoassays might yield variable results.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Beta-2 Glycoprotein 1
Protein
LOINC Codes
- 44447-1 - B2 Glycoprot1 IgA SerPl IA-aCnc
- 44447-1 - B2 Glycoprot1 IgA SerPl IA-aCnc
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |